

Effects of 2-Benzoylbenzoic Acid on Viability and Nitric Oxide Production in HIG-82 Synovial Fibroblasts

Wan Nooremira Wan Rashidi¹, Nurul Syuhada Nordin¹,
Che Ku Dahlan Daud², Mohd Sofian Omar Fauzee³,
Zuraini Ahmad¹ and Muhammad Nazrul Hakim^{1,4*}

¹Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia.

²Discipline of Basic Health Sciences (Pharmacology and Toxicology), Faculty of Pharmacy, Universiti Sultan Zainal Abidin (UniSZA), Terengganu, Malaysia.

³INTI International University, Nilai, Negeri Sembilan, Malaysia.

⁴Halal Product Institute, Universiti Putra Malaysia, Serdang, Malaysia.

*Corresponding Author E-mail:nazrulh@upm.edu.my

<https://dx.doi.org/10.13005/bpj/3382>

(Received: 09 February 2026; accepted: 16 March 2026)

Rheumatoid arthritis (RA) is characterized by persistent synovial inflammation, with synovial fibroblasts playing a key role in producing inflammatory mediators. 2-Benzoylbenzoic acid, known for its inhibitory activity against Aldo-keto reductase 1C3 (AKR1C3), was investigated for its effects on rabbit synovial fibroblasts (HIG-82) cell viability and nitric oxide (NO) production, both at rest and following stimulation with phorbol-12-myristate 13-acetate (PMA). Cells were treated with 2-benzoylbenzoic acid (3.125–300 μ M) for 24, 48, or 72 hours, with or without PMA (10 nM). Reference NSAIDs, diclofenac and ibuprofen (100 μ M), served as controls. The Griess reaction was used to evaluate nitrite concentrations in culture supernatants, and the MTT assay was used to assess cell viability. PMA significantly reduced cell viability over time compared to non-stimulated controls (24 h: 80.82 \pm 8.70%; 48 h: 59.70 \pm 12.50%; 72 h: 44.94 \pm 8.40%). In non-stimulated cells, viability was generally maintained at concentrations =200 μ M, whereas 300 μ M reduced viability at 24 hours (67.75 \pm 14.42%). In PMA-stimulated cells, viability at 72 hours was higher with 2-benzoylbenzoic acid (61.87–83.29%) than with PMA alone. Nitrite levels remained low, variable, and were not consistently decreased by the treatments, indicating that 2-benzoylbenzoic acid did not demonstrate an NO-linked anti-inflammatory effect under these conditions. Notably, despite its AKR1C3 inhibitory potential, 2-benzoylbenzoic acid did not suppress nitrite production, and no clear anti-inflammatory activity via NO modulation was observed.

Keywords: 2-benzoylbenzoic acid; Cell viability; Nitrite; Phorbol-12-myristate 13-acetate; Synovial fibroblasts.

Chronic synovitis, increasing joint degeneration, pain, and disability are the hallmarks of rheumatoid arthritis (RA), a systemic inflammatory disease.^{1,2} Within the inflamed synovium, fibroblast-like synoviocytes can adopt an

activated phenotype that promotes pannus formation and sustains inflammation through the release of cytokines, chemokines, and matrix-degrading enzymes.³ Despite major therapeutic advances,⁴ incomplete responses and adverse effects remain

practical barriers for some patients, supporting continued interest in alternative anti-inflammatory scaffolds. Conventional disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate, sulfasalazine, and hydroxychloroquine, have been widely used; however, they are associated with toxicity, delayed onset of action, and sometimes inadequate efficacy.^{5,6} However, they are associated with toxicity, delayed onset of action, and sometimes inadequate efficacy.⁶ This ongoing challenge supports continued interest in alternative anti-inflammatory scaffolds. Because there is no definitive cure, current therapies aim to control inflammation, relieve symptoms, and prevent structural damage using DMARDs and adjunct agents such as non-steroidal anti-inflammatory drugs (NSAIDs).^{7,8}

2-benzoylbenzoic acid (Figure 1) is a benzoic-acid derivative reported to inhibit aldo-keto reductase 1C3 (AKR1C3), an enzyme involved in prostaglandin and steroid metabolism.³ Physicochemical information on 2-benzoylbenzoic acid is available in curated chemical databases.⁹ Nitric oxide (NO) has been implicated in inflammatory tissue injury, and nitrite accumulation in culture medium is commonly used as a practical proxy for NO production in cell-based assays.^{10, 11} In this study, we tested whether 2-benzoylbenzoic acid influences viability and nitrite production in HIG-82 synovial fibroblasts under basal conditions and after PMA stimulation.

MATERIALS AND METHODS

Chemicals and Reagents

Sigma-Aldrich (St. Louis, MO, USA) supplied the 2-benzoylbenzoic acid, PMA, ibuprofen, diclofenac, MTT, and Griess reagents. Dimethyl sulfoxide (DMSO) was used to generate stock solutions, which were then diluted in culture medium until the final DMSO content was less than 0.1% (v/v).

Cell culture

HIG-82 rabbit synovial fibroblasts (ATCC® CRL-1832™; Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin at 37°C in a humidified incubator with 5% CO₂, as previously described.¹² Briefly, HIG-82 synoviocyte cell line

was kept in culture medium supplemented with 10% of foetal bovine serum (FBS; Biowest, South America), 100 U/ml penicillin (Biowest) and 100 ig/ml streptomycin (Biowest). Culture medium was changed every 3-4 days. After entering the confluence, which took 2–3 weeks, cells were subcultured serially using a solution of 0.25% Trypsin-EDTA with a subculture ratio of 1:2 to 1:4 and subjected to experiments below passage 10.

Experimental design

After being seeded onto 96-well plates and given an overnight period to adhere, the cells were treated to PMA (10 nM) as needed. Cells were treated with 2-benzoylbenzoic acid (3.125–300 μM); ibuprofen and diclofenac (100 μM) served as reference NSAIDs. Incubations were conducted for 24, 48, or 72 h. Detailed methods and calculations were published previously.^{7,12}

MTT assay

After incubation, culture medium was removed and 20 μL of 5mg/ml MTT solution was added to each well.¹² Plates were incubated until formazan crystals formed, the crystals were solubilized in DMSO, and absorbance was read using a microplate reader. Viability was expressed as a percentage of the relevant control.¹³

Griess assay for nitrite

Culture supernatants were collected and nitrite concentrations were determined using the Griess reaction with sodium nitrite standards as previously described.¹⁴

Statistical analysis

Data from three independent experiments are presented as mean ± standard error of the mean (SEM). Comparisons among groups were performed using one-way ANOVA followed by Tukey's post hoc test.¹⁵ A p-value of less than 0.05 was considered statistically significant.

RESULTS

Summary data for cell viability and nitrite production are shown in Tables 1–4. After 24 h, 2-benzoylbenzoic acid produced minimal cytotoxicity in non-stimulated HIG-82 cells across 3.125–200 μM, with viability remaining close to baseline (81.41% to 101.60%). A more marked reduction was observed at 300 μM (67.75 ± 14.42%; Table 1). In PMA-stimulated cells, PMA alone reduced viability to 80.82 ±

8.70%. Co-treatment with 2-benzoylbenzoic acid at concentrations of 3.125–300 μM resulted in viability values ranging from 67.39% to 92.72%, without a consistent concentration-dependent effect observed at 24 hours (Table 1). At the same time point, the reference drugs (100 μM) produced viabilities of $96.08 \pm 22.07\%$ (ibuprofen) and $97.70 \pm 21.80\%$ (diclofenac) in PMA-stimulated cells (Table 1).

Nitrite levels measured at 24 h were low and highly variable in both non-stimulated and PMA-stimulated conditions. For 2-benzoylbenzoic acid (50–200 μM), nitrite concentrations fluctuated without a consistent concentration-dependent decrease in either condition (Table 2). In PMA-stimulated cells, several mean values were near




Fig. 1. Chemical structure of 2-Benzoylbenzoic acid ($\text{C}_{14}\text{H}_{10}\text{O}_3$; MW of 226.23 g/mol)

zero, indicating no reproducible suppression pattern across concentrations under the present assay conditions (Table 2).

At 48 h, PMA exposure reduced viability to $59.70 \pm 12.50\%$ (Table 3). In non-stimulated cells, viability remained stable across 3.125–300 μM 2-benzoylbenzoic acid (83.82% to 91.71%). In PMA-stimulated cells, most concentrations of 2-benzoylbenzoic acid produced viabilities between 58.38% and 67.97%, while the highest concentration (300 μM) substantially reduced viability to $32.65 \pm 14.64\%$ (Table 3). Under PMA stimulation, ibuprofen (100 μM) yielded $66.22 \pm 14.58\%$, while diclofenac (100 μM) yielded $74.32 \pm 13.65\%$ at 48 h (Table 3).

By 72 h, PMA alone further reduced viability to $44.94 \pm 8.40\%$ (Table 4). In PMA-stimulated cells treated with 2-benzoylbenzoic acid, viability ranged from 61.87% to 83.29% across 3.125–300 μM , with the lowest mean viability observed at 300 μM ($61.87 \pm 20.11\%$; Table 4). At 72 h under PMA stimulation, ibuprofen and diclofenac produced viabilities of $68.10 \pm 11.76\%$ and $73.21 \pm 14.92\%$, respectively (Table 4).

DISCUSSION

In this study, we investigated the effects of 2-benzoylbenzoic acid on cell viability and

Table 1. Cell viability of non-stimulated and PMA-stimulated HIG-82 cells after 24 h treatment

Compound	Concentration (μM)	Cell Viability (%)	
		Non-induced	PMA-induced
Control (Normal cells)	0	100.01 ± 2.90	-
PMA-Induced (Negative Control)	0	-	80.82 ± 8.70
2-Benzoylbenzoic Acid	3.125	89.64 ± 10.13	85.59 ± 24.95
	6.25	101.60 ± 3.20	87.70 ± 20.35
	12.5	99.45 ± 6.41	89.84 ± 19.44
	25	94.13 ± 21.51	92.72 ± 25.09
	50	88.95 ± 13.42	80.66 ± 12.69
	100	87.92 ± 15.85	72.37 ± 8.18
	200	81.41 ± 14.38	72.85 ± 11.64
	300	$67.75 \pm 14.42^*$	67.39 ± 10.86
Ibuprofen	100	104.09 ± 5.31	96.08 ± 22.07
Diclofenac	100	106.18 ± 13.05	97.70 ± 21.80

*; significant difference compared with positive control drugs, Ibuprofen and Diclofenac. All values are presented as mean \pm SEM of 3 separate experiments.

nitric oxide (NO)-related nitrite production in HIG-82 synovial fibroblasts under basal and PMA-stimulated conditions. Our findings demonstrate that PMA induces a significant, time-dependent reduction in cell viability from 24 to 72 hours, consistent with its role as an inflammatory activator that imposes cellular stress, as reported in previous studies.¹⁶ The ability of PMA to activate NF- κ B pathways and promote inflammatory mediator production makes it a relevant model for studying synovial inflammation *in vitro*.

Regarding cytotoxicity, 2-benzoylbenzoic acid did not exhibit a clear concentration-dependent reduction in viability at doses ≥ 200 μ M under basal conditions, aligning with prior reports that

phenolic acids often display low cytotoxicity within this concentration range.³ Notably, at 300 μ M, viability decreased at 24 hours, and under PMA stimulation, there was a marked reduction at 48 hours, indicating potential cytotoxic effects at higher concentrations. Interestingly, several concentrations showed higher MTT signals than PMA alone at 72 hours, which could suggest partial protection against PMA-induced stress. However, as the MTT assay primarily measures mitochondrial metabolic activity, these apparent improvements could reflect altered cellular metabolism rather than true increases in cell number or survival. Similar phenomena have been observed in studies where phenolic compounds modulate mitochondrial

Table 2. Nitrite concentration in culture supernatant of non-stimulated and PMA-stimulated HIG-82 cells after 24 h treatment (Griess assay)

Compound	Concentration (μ M)	NO concentration (μ M) Non-induced	NO concentration (μ M) PMA-induced
2-Benzoylbenzoic Acid	50	0.56 \pm 5.55	3.35 \pm 11.74
	100	7.95 \pm 6.00	0.04 \pm 13.06
	200	3.71 \pm 3.03	0.00 \pm 14.92
Ibuprofen	100	8.92 \pm 5.48	0.00
Diclofenac	100	9.55 \pm 15.26	0.00

Values are mean \pm SEM of three independent experiments.

Table 3. Cell viability of non-stimulated and PMA-stimulated HIG-82 cells after 48 h treatment

Compound	Concentration (μ M)	Cell Viability (%) Non-induced	Cell Viability (%) PMA-induced
Control (Normal cells)	0	100.17 \pm 4.20	-
PMA-Induced (Negative Control)	0	-	59.70 \pm 12.50*
2-Benzoylbenzoic Acid	3.125	87.71 \pm 11.54	63.38 \pm 14.34*
	6.25	91.71 \pm 8.71#	67.97 \pm 12.10***
	12.5	84.31 \pm 3.08#	67.69 \pm 12.79***
	25	87.81 \pm 5.78#	67.96 \pm 12.94***
	50	84.34 \pm 5.42#	64.61 \pm 7.32*
	100	84.41 \pm 2.26#	58.38 \pm 3.73*
	200	85.84 \pm 3.64#	61.47 \pm 4.86*
300	83.82 \pm 11.48	32.65 \pm 14.64**	
Ibuprofen	100	85.83 \pm 4.04#	66.22 \pm 14.58*
Diclofenac	100	92.13 \pm 12.17#	74.32 \pm 13.65

**; significant difference compared with positive control drugs, Ibuprofen and Diclofenac.

***; significant difference compared with 300 μ M of 2-Benzoylbenzoic acid in PMA-induced cell line.

*; significant difference compared with normal control.

#; significant difference compared with negative control.

All values are presented as mean \pm SEM of 3 separate experiments.

Table 4. Cell viability of non-stimulated and PMA-stimulated HIG-82 cells after 72 h treatment

Compound	Concentration (μ M)	Cell Viability (%) Non-induced	Cell Viability (%) PMA-induced
Control (Normal cells)	0	100.90 \pm 5.10	-
PMA-Induced (Negative Control)	0	-	44.94 \pm 8.40*
2-Benzoylbenzoic Acid	3.125	100.17 \pm 6.02**	83.29 \pm 14.35
	6.25	102.99 \pm 3.86**	78.91 \pm 16.25
	12.5	87.78 \pm 8.21**	76.52 \pm 17.96
	25	92.55 \pm 8.74**	79.81 \pm 17.09
	50	89.29 \pm 7.65**	77.32 \pm 14.58
	100	88.76 \pm 6.81**	75.15 \pm 16.99
	200	92.75 \pm 8.99**	71.42 \pm 9.32
	300	89.43 \pm 8.19**	61.87 \pm 20.11
Ibuprofen	100	89.91 \pm 6.59**	68.10 \pm 11.76
Diclofenac	100	89.91 \pm 8.14**	73.21 \pm 14.92

All values are presented as mean \pm SEM of 3 separate experiments.

*; significant difference compared with normal control.

**; significant difference compared with negative control.

function without affecting viability directly.²¹ To clarify these effects, complementary assays such as live/dead staining, DNA quantification, or automated cell counting should be employed, as suggested by other investigations into flavonoid and phenolic acid effects on synovial cells.²²

PMA is well-established as an activator of inflammatory signaling, including NF- κ B pathways,¹⁶ which are central to synovial inflammation and rheumatoid arthritis (RA) progression. NF- κ B activation leads to increased production of proinflammatory cytokines, matrix metalloproteinases, and other mediators that contribute to joint destruction.^{16,17} Therefore, agents that modulate this pathway hold therapeutic potential.

In terms of inflammatory mediator production, we observed that nitrite levels were low and highly variable, with no consistent suppression by 2-benzoylbenzoic acid. Although NO is implicated in RA pathogenesis, contributing to cartilage matrix degradation under IL-1 stimulation¹⁰, synovial fibroblasts may not produce a robust nitrite response upon PMA stimulation alone, as reported elsewhere.²³ This suggests that nitrite as a sole endpoint may lack sensitivity in this context, especially when evaluating modest anti-inflammatory effects. Similar limitations

have been noted in studies where NO levels do not reliably reflect anti-inflammatory activity.²⁴ To improve assay sensitivity, future experiments could employ cytokine stimulation regimens involving TNF- α or IL-1 β , which more directly activate iNOS pathways.^{18,19} Including positive controls for NO inhibition, such as aminoguanidine, would also strengthen data interpretation.

The observed lack of reproducible nitrite suppression aligns with the known mechanisms of 2-benzoylbenzoic acid, which primarily inhibits AKR1C3, an enzyme involved more closely in prostaglandin and steroid metabolism than NO biology.³ This suggests that its anti-inflammatory effects may be mediated through pathways other than NO suppression. Supporting this, previous studies have shown that phenolic acids can modulate prostaglandin synthesis and steroidogenic pathways, which are relevant in inflammatory diseases.²⁵ Therefore, future research should broaden outcome measures to include COX-2 expression, prostaglandin E₂ production, and cytokines such as IL-6, providing a more comprehensive assessment of anti-inflammatory potential.²⁰

In comparison to other studies, phenolic acids and related compounds have demonstrated varying degrees of anti-inflammatory activity, often

linked to their antioxidant capacity and modulation of enzymatic pathways involved in prostaglandin synthesis.²⁶ Our findings contribute to this body of evidence, suggesting that 2-benzoylbenzoic acid may exert its effects primarily through modulation of prostaglandin metabolism rather than direct NO inhibition.

CONCLUSION

Overall, within the limits of the current HIG-82/PMA conditions and the variability of the nitrite assay, the data do not provide convincing evidence for robust NO-linked anti-inflammatory activity of 2-benzoylbenzoic acid. More informative stimulation and additional endpoints are needed before firm conclusions can be drawn.^{21, 22} The nitrite readout was close to baseline and variable, suggesting that PMA alone may not have induced a sufficiently robust iNOS/NO response to detect modest inhibition. Because MTT reflects cellular metabolic activity rather than direct cell number, orthogonal viability measures such as live/dead assays or direct counting are recommended. Follow-up experiments should consider cytokine-based stimulation (e.g., TNF- α and/or IL-1 β), include a positive control for NO/iNOS inhibition, and expand inflammatory endpoints to COX-2/PGE2 and cytokines especially IL-6.

ACKNOWLEDGEMENT

The authors express their thanks to Universiti Putra Malaysia for providing the necessary facilities to carry out this research work.

Funding Sources

This work had been funded by the UPM Research University Grant Scheme (grant no. 9366100).

Conflicts of interest

The author(s) declare no conflicts of interest.

Data Availability Statement

This statement does not apply to this article.

Ethics Statement

This research did not involve human participants, animal subjects, or any material that requires ethical approval.

Informed Consent Statement

This study did not involve human participants, and therefore, informed consent was not required.

Clinical Trial Registration

This research does not involve any clinical trials.

Permission to reproduce material from other sources

Not Applicable.

Author contributions

Wan Nooremira Wan Rashidi conducted experiments and drafted the initial manuscript; Nurul Syuhada Nordin, Che Ku Dahlan Daud, Mohd Sofian Omar Fauzee, and Zuraini Ahmad contributed to study design, supervision, and manuscript review; Muhammad Nazrul Hakim supervised the project and approved the final version.

REFERENCES

1. Wu D, Luo Y, Li T, Zhao X, Lv T, Fang G, et al. Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment. *Front. Immunol.* 2022; 13:1051082. doi: 10.3389/fimmu.2022.1051082
2. Alhatim H, Alshadfan H, Omar Fauzee MS, Zakaria ZA, Hakim MN. Analyzing NSAIDs research trends: a six-year bibliometric study (2018-2023) on directions, themes, and dimensions. *Multidisciplinary Reviews.* 2026;9(3):2026130. doi:10.31893/multirev.2026130
3. Lee SC, Tsai PH, Chan TM, Yu KH. Fibroblast-like Synoviocytes as Key Regulators of Homeostasis and Inflammation in the Joint Microenvironment of Inflammatory Arthritis. *Biomedicines.* 2026; 14(2):396. doi:10.3390/biomedicines14020396
4. Bharti JL, Wankhade A, Morey P, Ruikar P. The role of obesity in cancer incidence, treatment, and outcomes. *Medical and Pharmaceutical Journal.* 2023 Oct 10;2(3):181-92. DOI: 10.55940/medphar202340
5. Mousavi MJ, Karami J, Aslani S, Tahmasebi MN, Vaziri AS, Jamshidi A, Farhadi E, Mahmoudi M. Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe. *Auto Immun Highlights.* 2021; 12(1):3. doi: 10.1186/s13317-020-00145-x
6. Huang C, Liang Y, Li Y, Wei Q, Ouyang L, Zhang J. The epigenetic landscape of rheumatoid

- arthritis: pathogenesis and drug therapeutic potentials. *Acta Pharm Sin B*. 2025;15(11):5601-5631. doi:10.1016/j.apsb.2025.08.022
7. Dahlan-Daud CK, Zain ZN, Tham CL, Yong YK, Hakim MN. Effects of 4 thiopurine compounds on nitric oxide production and cell viability of HIG-82 synoviocytes and RAW 264.7 macrophages. *Biomed Pharmacol J*. 2020;13(3). doi:10.13005/bpj/1974
 8. Alshadfan H, Qais J, Omar Fauzee MS, Zakaria ZA, Yong YK, Hakim MN. Non-steroidal anti-inflammatory drug-induced gastric ulcers: a review on some current issues. *Trop J Pharm Res*. 2025;24(6). doi:10.4314/tjpr.v24i6.11
 9. National Center for Biotechnology Information (NCBI). PubChem Compound Summary for CID 6813, 2-benzoylbenzoic acid. PubChem website. Accessed January 27, 2026. <https://pubchem.ncbi.nlm.nih.gov/compound/2-Benzoylbenzoic-Acid>
 10. Voros C, Sapantzoglou I, Mavrogianni D, Athanasiou D, Varthaliti A, Bananis K, et al. Unlocking Implantation: The Role of Nitric Oxide, NO₂-NO₃, and eNOS in Endometrial Receptivity and IVF Success-A Systematic Review. *International Journal of Molecular Sciences*. 2025; 26(14):6569. doi:10.3390/ijms26146569
 11. Andrabhi SM, Sharma NS, Karan A, Shahriar SMS, Cordon B, Ma B, Xie J. Nitric Oxide: Physiological Functions, Delivery, and Biomedical Applications. *Adv Sci (Weinh)*. 2023;10(30):e2303259. doi: 10.1002/advs.202303259
 12. Dahlan-Daud C. K, Zain Z. N, Tham C. L, Yong Y. K, Hakim M. N. Effects of 4 Thiopurine Compounds on Nitric Oxide Production and Cell Viability of HIG-82 Synoviocytes and RAW 264.7 Macrophages. *Biomed Pharmacol J* 2020;13(3).
 13. Buranaamnuay K. The MTT assay application to measure the viability of spermatozoa: A variety of the assay protocols. *Open Vet J*. 2021;11(2):251-269. doi: 10.5455/OVJ.2021.v11.i2.9.
 14. Brizzolari A, Dei Cas M, Cialoni D, Marroni A, Morano C, Samaja M, Paroni R, Rubino FM. High-Throughput Griess Assay of Nitrite and Nitrate in Plasma and Red Blood Cells for Human Physiology Studies under Extreme Conditions. *Molecules*. 2021; 26(15):4569. doi: 10.3390/molecules26154569
 15. Almukram AM, Al-hussaniy HA, Jabarah MA, Al-Abdeen SH. MDM2 antagonists and p53-targeting therapies in cancer: clinical applications, adverse effects, and resistance mechanisms. *Medical and Pharmaceutical Journal*. 2025 Apr 4;4(1):47-63. Doi:10.55940/medphar202567
 16. Veh J, Mangold C, Felsen A, Ludwig C, Gerstner L, Reinhardt P, et al. Phorbol-12-myristate-13-acetate is a potent enhancer of B cells with a granzyme B⁺ regulatory phenotype. *Front Immunol*. 2023;14:1194880. doi:10.3389/fimmu.2023.1194880
 17. Hakim M, McCarthy EF. Heterotopic mesenteric ossification. *AJR Am J Roentgenol*. 2001;176(1):260-261. doi:10.2214/ajr.176.1.1760260
 18. Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M, et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. *Signal Transduct Target Ther*. 2023;8:68. doi:10.1038/s41392-023-01331-9
 19. Fulda S, Gorman AM, Hori O, Samali A. Cellular stress responses: cell survival and cell death. *Int J Cell Biol*. 2010; 2010:214074. doi:10.1155/2010/214074
 20. Pagnini M, Visciglia A, Deusebio G, Pane M, Celi A, Amoroso A, Neri T. Dose-Dependent Anti-Inflammatory Effects of Live and Heat-Treated *Ligilactobacillus salivarius* and *Bifidobacterium breve* via NF- κ B and COX-2 Modulation in an In Vitro Model of Airway Inflammation. *Nutrients*. 2025; 17(15):2504. doi: 10.3390/nu17152504.
 21. Inkanuwat A, Sukaboon R, Reamtong O, Asawanonda P, Pattaratanakun A, Saisavoey T, Sangtanoo P, Karnchanat A. Nitric Oxide Synthesis Inhibition and Anti-Inflammatory Effect(of Polypeptide Isolated from Chicken Feather Meal(in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages. *Food Technol Biotechnol*. 2019; 57(2):200-212. doi: 10.17113/ftb.57.02.19.5964.
 22. Deane KD. Can rheumatoid arthritis be prevented? *Best Pract Res Clin Rheumatol*. 2013;27(4):467-485. doi:10.1016/j.berh.2013.09.002
 23. Huang JB, Chen ZR, Yang SL, Hong FF. Nitric Oxide Synthases in Rheumatoid Arthritis. *Molecules*. 2023; 28(11):4414. doi: 10.3390/molecules28114414.
 24. Ferrer MD, Reynés C, Jiménez L, Malagraba G, Monserrat-Mesquida M, Bouzas C, Sureda A, Tur JA, Pons A. Nitrite Attenuates the *In Vitro* Inflammatory Response of Immune Cells to the SARS-CoV-2 S Protein without Interfering in the Antioxidant Enzyme Activation. *International Journal of Molecular Sciences*. 2024; 25(5):3001. doi:10.3390/ijms25053001
 25. Penning TM. Aldo-Keto Reductase (AKR) IC3 inhibitors: a patent review. *Expert Opin Ther Pat*. 2017;27(12):1329-1340. doi:

- 10.1080/13543776.2017.1379503.
26. Rahman MM, Rahaman MS, Islam MR, Rahman F, Mithi FM, Alqahtani T, Almikhlafi MA, Alghamdi SQ, Alruwaili AS, Hossain MS, Ahmed M, Das R, Emran TB, Uddin MS. Role of Phenolic Compounds in Human Disease: Current Knowledge and Future Prospects. *Molecules*. 2021;27(1):233. doi: 10.3390/molecules27010233. 3